Hostname: page-component-78c5997874-ndw9j Total loading time: 0 Render date: 2024-11-16T15:26:03.274Z Has data issue: false hasContentIssue false
  • English
  • Français

Monoclonal Antibodies and Progressive Multifocal Leukoencephalopathy

Published online by Cambridge University Press:  02 December 2014

Daniel L. Keene ,
Carole Legare ,
Elaine Taylor ,
Jim Gallivan ,
Gloria Mah Cawthorn  and
Duc Vu
Daniel L. Keene*
Affiliation:
Biotechnology and Natural Health Products Bureau, Ottawa, Ontario, Canada
Carole Legare
Affiliation:
Biotechnology and Natural Health Products Bureau, Ottawa, Ontario, Canada
Elaine Taylor
Affiliation:
Biotechnology and Natural Health Products Bureau, Ottawa, Ontario, Canada
Jim Gallivan
Affiliation:
Biotechnology and Natural Health Products Bureau, Ottawa, Ontario, Canada
Gloria Mah Cawthorn
Affiliation:
Biotechnology and Natural Health Products Bureau, Ottawa, Ontario, Canada
Duc Vu
Affiliation:
Biotechnology and Natural Health Products Bureau, Ottawa, Ontario, Canada
*
Marketed Biologicals, Biotechnology and Natural Health Products Bureau, 200 Tunney's Pasture Driveway, Ottawa, Ontario, K1A 0K9, Canada
Rights & Permissions [Opens in a new window]

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

Monoclonal antibodies have become an important treatment option for a number of serious conditions. Concerns have arisen about the potential association of these products with progressive multifocal leukoencephalopathy (PML). A list of monoclonal antibodies authorized for sale was derived from the Health Canada Drug Product Database. Case reports of PML after exposure to a monoclonal antibody authorized for use in Canada were retrieved by searching Canada Vigilance and WHO adverse event databases and through a Pub MED/Medline literature search. 182 adverse event case reports were retrieved (adalimumab -1 case, alemtuzumab-14, bevacizumab -3, cetuximab -1, efalizumab - 8, ibritumomab tiuxetan-5, infliximab-4, natalizumab-32, and rituximab-114). The Canadian Product Monographs for natalizumab and ritiximab contain box warnings for PML. A natalizumab registry has been established.

Type
Review Article
Information
Canadian Journal of Neurological Sciences , Volume 38 , Issue 4 , July 2011 , pp. 565 - 571
Copyright
Copyright © The Canadian Journal of Neurological 2011

References

1.Psaty, B, Burke, S.Protecting the Health of the Public-Institute of Medicine recommendations on drug safety. N Eng J Med. 2006 (17);315:1753–5.Google Scholar
2.Talbot, J, Nilsson, B.Pharmacovigilance in the pharmaceutical industry. Br J Clin Pharmacol. 1998;45(5):427–31.Google Scholar
3.Simon, L.Pharmacovigilance: towards a better understanding of the benefit to risk ratio. Ann Rheum Dis. 2002 Nov;61 Suppl 2: ii88–9.Google Scholar
4.Fletcher, A.Spontaneous adverse drug reaction reporting vs event monitoring: a comparison. J R Soc Med. 1991;84(6):341–4.Google Scholar
5.Koralnik, I.Progressive multifocal Leukoencephalopathy revisited: has the disease outgrown its name? Ann Neurol. 2006;60(2):162–73.Google Scholar
6.Major, E.Progressive multifocal leukoencephalopathy in patients on immunomodulatory therapies. Ann Rev Med. 2010;61:35–47.Google Scholar
7.Berger, J.Progressive multifocal leukoencephalopathy. Curr Neurol Neurosc Rep. 2007;7:461–9.CrossRefGoogle ScholarPubMed
8.Khalili, K, White, M, Lublin, Fet al.Reactivation of JC virus and development of PML in patients with multiple sclerosis. Neurology. 2007;68(13):985–90.CrossRefGoogle ScholarPubMed
9.Aksamit, A.Review of progressive multifocal leukoencephalopathy and natalizumab. Neurologist. 2006;12(6):293–8.CrossRefGoogle ScholarPubMed
10.Berger, J, Houff, S.Progressive multifocal leukoencephalopathy: lessons from AIDS and natalizumab. Neurol Res. 2006;28(3):299–305.CrossRefGoogle ScholarPubMed
11.Carson, K, Focosi, D, Major, E, et al.Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natilizumab, and efalizumab: a review from the Research on Adverse Drug Events and Reports (RADAR) Project. Lancet Oncol. 2009;10(8):816–24.CrossRefGoogle ScholarPubMed
12.Martin, S, Marty, F, Fiumara, K, Treon, S, Gribben, J, Baden, L.Infectious complications associated with alemtuzumab use in lymphoproliferative disorders. Clin Infect Dis. 2006;43(1):16–24.Google Scholar
13.Jiang, M, Abend, J, Johnson, S, Imperiale, M.The role of polyomaviruses in human disease. Virology. 2009;384(2):266–73.Google Scholar
14.Khalili, K, Gordon, J, White, M.The polyomavirus, JC and its involvement in human disease. Adv Exp Med Biol. 2006;577:274–87.Google Scholar
15.Major, E, Amemiya, K, Tornatore, C, Houff, S, Berger, J.Pathogenesis and molecular biology of progressive multifocal leukoencephalopathy, JC virus-induced demyelinating disease of the human brain. Clin Microbiol Rev. 1992;5(1):49–73.CrossRefGoogle ScholarPubMed
16.Sweet, T, Del Valle, L, Kalili, K.Molecular biology and immunoregulation of human neurotropic JC virus in CNS. J Cell Physiol. 2002;191(3):249–56.Google Scholar
17.Agostini, H, Ryschkewitsch, C, Stoner, G.Genotype profile of human polyomavirus JC excreted in urine of immunocompetent individuals. J Clin Microbiol. 1996;34(1):159–64.CrossRefGoogle ScholarPubMed
18.Walker, D, Padgett, B.The epidemiology of human polyomavirus. Prog Clin Biol. Res. 1983;105:99–106.Google Scholar
19.Knowles, W.Discovery and epidemiology of human polyomaviruses BK virus (BKV) and JC virus (JCV). Adv Exp Med Biol. 2006;577:19–45.Google Scholar
20.Seth, P, Diaz, F, Major, E.Advances in the biology of JC virus and induction of progressive multifocal leukoencephalopathy. J Neuro Virol. 2003;9(2):236–46.Google Scholar
21.Mori, M, Aoki, N, Shimada, H, Tajima, M, Kato, K.Detection of JC virus in the brains of aged patients without progressive multifocal leukoencephalopathy by the polymerase chain reaction and Southern hybridication analysis. Neurosci Lett. 1992;141(2):151–5.Google Scholar
22.Perez-Liz, G, Del Valle, L, Gentilella, A, Croul, S, Khalili, K.Detection of JC virus DNA fragments but not proteins in normal brain tissue. Ann Neurol. 2008;64(4):379–87.CrossRefGoogle Scholar
23.White, F, Ishaq, M, Stoner, G, Frisque, R.JC virus DNA is present in many human brain samples from patients without progressive multifocal leukoencephalopathy. J Virol. 1992;66(10):5726–34.Google Scholar
24.Newman, J, Frisque, R.Identification of JC virus variants in multiple tissues of pediatric and adult PML patients. J Med Virol. 1999;58 (1):79–86.Google Scholar
25.Debue, S, Branchetti, E, Berolacci, Set al.JC virus VP1 loop-specific polymorphisms are associated with favourable prognosis for progressive multifocal leukoencephalopathy. J Neurovirol. 2009;15(1):51–6.Google Scholar
26.Dubois, V, Dutronic, H, Lafon, M, et al.Latency and reactivation of JC virus in peripheral blood of human immunodeficiency virus type1-infected patients. J Clin Microbiol. 1997;35(9):2288–92.CrossRefGoogle ScholarPubMed
27.Bartt, R.Multiple sclerosis, natalizumab therapy, and progressive multifocal leukoencephalopathy. Curr Opin Neurol. 2006;19(4):341–9.Google Scholar
28.Clifford, D, Del, A, Simpson, D, Arendt, G, Giovannoni, G, Nath, A.Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lesions from 28 cases. Lancet Neurol. 2010:9(4):438–46.Google Scholar
29.Hartung, H.New cases of progressive multifocal leukoencephalopathy after treatment with natalizumab. Lancet Neurol. 2009;8(1):28–9.Google Scholar
30.Langer-Gould, A, Atlas, S, Green, A, Bollen, A, Pelletier, D.Progressive multifcoal leukoencephalopathy in a patient treated with natalizumab. N Eng J Med. 2005;353(4):375–81.Google Scholar
31.Kleinschmidt-DeMasters, B, Tyler, B.Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1 a for multiple sclerosis. N Eng J Med. 2005;353(4):369–74.Google Scholar
32.Linda, H, von Heijne, A, Major, E, et al.Progressive multifocal leukoencephalopathy after natalizumab monotherapy. N Eng J Med. 2009;361(11):1081–7.Google Scholar
33.Major, E.Reemergence of PML in natalizumab-treated patientsnew cases, same concerns. N Eng J Med. 2009;36 (11)1:1041–3.CrossRefGoogle Scholar
34.Yousry, T, Major, E, Ryschkewitsch, C, et al.Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Eng J Med. 2006;354(9):924–33.Google Scholar
35.Wenning, W, Haghikia, A, Laudenberger, J, et al.Treatment of progressive multifocal leukoencephalopathy associated with natalizumab. N Eng J Med. 2009;361(11):1075–80.Google Scholar
36.van Assche, G, Van Ranst, M, Sciot, R, et al.Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn’s disease. N Eng J. Med. 2005;353(4):362–8.Google Scholar
37.Boren, E, Cheema, G, Naguma, S, Anasari, A, Gershwin, E.The emergence of progressive multifocal leukoencephalopathy (PML) in rheumatic diseases. J Autoimmun. 2008;30(1-2):90–8.CrossRefGoogle ScholarPubMed
38.Carson, K, Evens, A, Richey, E, et al.Progressive multifocal leukoencephalopathy after rutixmab therapy in HIV-negative patients: a report of 57 cases from the Research onAdverse Drug Events and Reports project. Blood. 2009;113(20):4834–40.Google Scholar
39.D’Souza, A, Wilson, J, Mukherjee, S, Jaiyesimi, I.Progressive multifocal leukoencephalopathy in chronic lymphocytes leukemia: a report of three cases and review of the literature. Clinical Lymph Myeloma Leuk. 2010;10(1):E1–9.Google Scholar
40.Fleischmann, R.Progressive multifocal leukoencephalopathy following rutiximab treatment in a patient with rheumatoid arthritis. Arthritis Rheum. 2009;60(11):3225–8.Google Scholar
41.Harris, H.Progressive multifocal leucoencephalopathy in a patient with systemic lupus erythematosus treated with rituximab. Rheumatology (Oxford). 2008;47(2):225–6.Google Scholar
42.Hopfinger, G, Plessl, A, Grisold, W, et al.Progressive multifocal leukoencepatholopathy after rituximab in a patient with relapsed follicular lymphoma and low IgG levels and a low CD4+ lymphocyte count. Leuk Lymphoma. 2008;49(12):2367–9.CrossRefGoogle Scholar
43.Kranick, S, Mowry, E, Rosenfeld, M.Progressive multifocal leukoencephalopathy after rituxamab in case of non-Hodgkin lymphoma. Neurology. 2007;9(24):704–6.Google Scholar
44.Matteucci, P, Magni, M, Di Nicola, M, Carlo-Stella, C, Uberti, C, Gianni, A.Leukoencephalopathy and papavirus infection after treatment with chemotherapy and anti-CD20 monoclonal antibody. Blood. 2002;100(3):1104.CrossRefGoogle ScholarPubMed
45.Ram, R, Ben-Bassat, I, Shipilberg, O, Polliack, A, Raanani, P.The late adverse events of rituximab therapy-rare but there! Leuk Lymphoma. 2009;50(7):1083–95.Google Scholar
46.Freim Wahl, S, Folvik, M, Torp, S.Progressive multifocal leukoencephalopathy in a lymphoma patient with complete remission after treatment with cystostatics and rituxuamb: a case report and review of the literature. Clin Neuropathol. 2007;26 (2):68–73.CrossRefGoogle Scholar
47.Yokoyama, H, Watanabe, T, Maruyama, D, Kim, S, Kobayashi, Y, Tobinai, K.Progressive multifocal leukoencephalopathy in a patient with B-cell lymphoma during rituximab-containing chemotherapy: a case report and review of the literature. Int J Hematol. 2008;88(4):443–7.CrossRefGoogle Scholar
48.Waggoner, J, Martinu, T, Palmer, S.Progressive multifocal leukoencephalopathy following heightened immunosuppression after lung transplant. J Heart Lung Transplant. 2009;28(4):395–8.Google Scholar
49.Uppenkamp, M, Engert, A, Deihl, V, Bunjes, D, Huhn, D, Brittinger, G.Monoclonal antibody therapy with CAMPATH-1H in patients with relapsed high and low-grade non-Hodgkin’s lymphoma: a multicenter phase I/II study. Ann Hematol. 2002;81(1):26–32.Google Scholar
50.Korman, B, Tyler, K, Korman, N.Progressive multifocal leukoencephalopathy, efalizumab, and immunosuppression. A cautionary tale for dermatologists. Arch Dermatol. 2009;145(8):937–42.Google Scholar
51.Malloy, E, Calabrese, L.Therapy: targeted but not trouble-free: efalizumab and PML. Nat Rev Rheumatol. 2009;5(8):418–19.CrossRefGoogle Scholar
52.Mohan, N, Edwards, E, Cupps, T, et al.Demyelination occurring during anti-tumor necrosis factor a therapy for inflammatory arthritides. Arthritis Rheum. 2001;44(12):2862–9.Google Scholar
53.Wu, J, Fung, M, Kwong, K, Hornbuckle, K, Muniz, E.Postmarketing drug safety surveillance. Pharm Dev Regul. 2003;1(4):231–44.CrossRefGoogle Scholar
54.http://www.hc-sc.gc.ca/dhp-mps/medeff/advisoriesavis/public/_2009/raptiva_2_pc-cp-eng.phpGoogle Scholar
55.Garcia-Suarez, J, Miguel, D, Krsnik, I, Banas, H, Arribas, I, Burgaleta, C.Changes in the natural history of progressive multifocal leukoencephalopathy in HIV-negative lymphoproliferative disorders: impact of novel therapies. Am J Hematol. 2005;80(4):271–81.Google Scholar
56.Cid, J, Revilla, M, Cervera, A, et al.Progressive multifocal leukoencephalopathy following oral fludarabine treatment with chronic lymphocytic leukemia. Ann Haematol. 2000;9(7):391–5.Google Scholar
57.http://www.hc-sc.gc.ca/dhp-mps/medeff/advisories-avis/public/_2007/rituxan_4_pc-cp-eng.phpGoogle Scholar
58.Berger, J, Houff, S, Major, E.Monoclonal antibodies and progressive multifocal leukoencephalopathy. MAbs. 2009;1(16):583–9.CrossRefGoogle ScholarPubMed
59.Terenant, D, Painfond, G.Pharmacokinetics and concentration-effect relationships of therapeutic monoclonal antibodies and fusion proteins. Expert Opin Biol Ther. 2005;5 Suppl 1:S37–47.Google Scholar